Drug Trial Radar · NCT06862453
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Mar 12, 2026
Primary completion
Aug 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Sanaria Inc.Industry
- Sponsor type
- Industry
- Collaborators
- University Hospital Tuebingen; UCLA David Geffen School of Medicine and Fielding School of Public Health; Stanford University; Leiden University
- First posted
- Mar 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy, malaria-naive study participants in Germany by direct venous inoculation (DVI) to determine safety, tolerability, and vaccine efficacy (VE) against controlled human malaria infection (CHMI). PfSPZ-LARC2 Vaccine contains a deletion of two genes, the Mei2 and LINUP genes, and undergoes developmental arrest in the late liver stages without releasing merozoites into the blood stream (blood stage parasites). The primary objective of the study is to assess the safety and tolerability of administration of PfSPZ-LARC2 Vaccine, with special attention to the adequacy of attenuation, in the intention-to-treat (ITT) population.
Conditions
- Malaria Falciparum
Interventions
Normal Saline (Placebo)Other
The blinded control group of the main cohorts will receive normal saline as placebo, also by DVI.
PfSPZ-LARC2 VaccineBiological
Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) contains a deletion of two genes, the Mei2 and LINUP genes, and undergoes developmental arrest in the late liver stages without releasing merozoites into the blood stream (blood stage parasites).
PfSPZ Challenge (7G8)Biological
Main cohort participants (verum and placebo) will undergo heterologous CHMI using DVI of 3.2x10\^3 PfSPZ of PfSPZ Challenge (7G8), which are infectious cryopreserved Pf sporozoites.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of administration of PfSPZ-LARC2 Vaccine, with special attention to the adequacy of attenuation, in the intention-to-treat (ITT) population: infectionTime frame: 28 days after immunization
- Safety and tolerability of administration of PfSPZ-LARC2 Vaccine, with special attention to the adequacy of attenuation, in the intention-to-treat (ITT) population: related AEsTime frame: 7 days after injection of PfSPZ-LARC2 Vaccine
- Safety and tolerability of administration of PfSPZ-LARC2 Vaccine, with special attention to the adequacy of attenuation, in the intention-to-treat (ITT) population: related SAEsTime frame: Time of first immunization to the end of the study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Tubingen
Tübingen, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.